NCT01014000

Brief Summary

Empirical implantation of the left ventricular lead is the prevailing practice in cardiac resynchronization therapy device implantation. The response rate to the therapy has been uniformly 70% only despite various methods to screen patients before device implantation. This study tested the hypothesis that echocardiography to assess acute resynchronization of the left ventricle during device implantation may improve the response rate to the therapy.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2015

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 13, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 16, 2009

Completed
5.5 years until next milestone

Study Start

First participant enrolled

June 1, 2015

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

September 4, 2015

Status Verified

September 1, 2015

Enrollment Period

Same day

First QC Date

November 13, 2009

Last Update Submit

September 3, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Clinical response (Improvement in functional class status by at least one NYHA Class or ≥10% increase in 6-minute hall walk distance) to CRT

    6 months after device implantation

Secondary Outcomes (3)

  • Echocardiographic response of ≥15% reduction in LVESV

    6 months after device implantation

  • Echocardiographic response of absolute increase of ≥5% in LVEF

    6 months after device implantation

  • Biochemical response with reduction of BNP level≥15%

    6 months after device implantation

Study Arms (2)

Empirical

ACTIVE COMPARATOR

Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation

Device: Empirical group

Echocardiography-guided approach

EXPERIMENTAL

Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation

Device: Echocardiography-guided approach

Interventions

Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation

Empirical

Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation

Echocardiography-guided approach

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with SR or AF, indicated for CRT procedures (NYHA Class III or ambulatory Class IV despite optimal medical therapy, QRSd≥120ms and LVEF≤35%)
  • Patients with ischaemic or non-ischaemic cardiomyopathy can be recruited

You may not qualify if:

  • Patients already implanted with an implantable cardiac device, undergoing device upgrade or generator replacement
  • Patients who aged less than 18 or over 80.
  • Patients who are pregnant.
  • Patients who cannot give informed consent.
  • Patients who are judged to have severe mental impairment and cannot report symptoms of heart failure during follow-up.
  • Patients who have comorbid congenital heart disease.
  • Patients who have severe valvular heart disease, apart from severe mitral regurgitation.
  • Patients who have unstable angina or who are within 1 month of myocardial infarction.
  • Patients who have severe lung disease and accurate clinical assessment for heart failure symptoms cannot be performed.
  • Patients who have poor echocardiographic windows precluding reliable echocardiographic examination during baseline assessment, CRT procedures or follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Princess Margaret Hospital

Hong Kong, 852, China

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Ngai Yin Chan, MBBS

    Princess Margaret Hospital, Canada

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

November 13, 2009

First Posted

November 16, 2009

Study Start

June 1, 2015

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

September 4, 2015

Record last verified: 2015-09

Locations